OTC: PURE · Industrial Applications and Services · 3 alerts · CIK 1006028
Share price
$0.0600Close, Nov 16
Market cap
$8.41M
Shares outstanding
140.2MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Miscellaneous Chemical ProductsSIC 2890
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pure Bioscience, Inc. filings on SEC EDGAR ↗
PURE Bioscience, Inc. is focused on commercializing its proprietary Silver Dihydrogen Citrate (SDC) technology for food safety, including PURE Hard Surface and PURE Control. The company faces significant financial challenges, including a history of losses and a going concern warning from its auditors, necessitating additional capital to maintain operations.
PURE Bioscience reported financial results for the fiscal year ended July 31, 2026, with net product sales increasing 5% to $2.3 million. The company posted a net loss of $2.5 million, or $0.02 per share, as growth in its end-user network was offset by a challenging macro environment and disruptions in the food industry.
Term
FY2026
“We are up year-over-year despite being a challenging year, with the macro environment causing increased expenses and foodborne outbreaks severely disrupting the food industry. Although our growth didn’t meet expectations, our focus remains on reducing costs and converting more opportunities into revenue.”
PURE Bioscience completed a private placement financing raising $555,000 through the issuance of 10,183,486 shares of common stock. The investment was made by board member Tom Y. Lee and his affiliates at a price of $0.0545 per share, with proceeds intended for research, development, and general working capital.